CJC-1295 (with DAC)
Fat LossLong-acting GHRH analogExperimental
Explicit DAC (albumin-binding) form of CJC-1295 with a multi-day half-life. Not FDA-approved. WADA S2.
For research use only.
Key Facts
- CAS
- 863288-34-0
- Molecular Weight (MW)
- ≈3647 g/mol
- Half-life
- ~6–8 days (albumin binding via DAC; human studies)
- Unit
- mcg
- Administration Route
- Subcutaneous (research contexts)
- Frequency
- —
- Last updated
- 8/23/2026
- Targets
- GHRH receptorSerum albumin (carrier)
Overview
Explicit DAC (albumin-binding) form of CJC-1295 with a multi-day half-life. Not FDA-approved. WADA S2.
Protocol
- Dosage Range
- Not established for approved medical use
- Frequency
- —
- Cycle
- —
- Administration Route
- Subcutaneous (research contexts)
- Reconstitution Guide
- —
Science
Mechanism of Action
GHRH analog conjugated to a DAC group that binds serum albumin, extending GH/IGF-1 elevation for days after a single injection in published human PK studies.
Targets
GHRH receptorSerum albumin (carrier)
Studies
- CJC-1295 DAC human PK/PD— Journal/year not available
Benefits
Infrequent GH-axis stimulation in research
Potential Side Effects
- Sustained IGF-1 rise
- Edema
- Paresthesia
References
- PMID 16352683External link · Year —
- WADA Prohibited List 2026External link · Year —